全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Pulmonary Arterial Hypertension in Congenital Heart Disease with Left-to-Right Shunt: According to a Retrospective Study at Albert Royer’s National Children’s Hospital Center

DOI: 10.4236/ojped.2023.135072, PP. 649-656

Keywords: PAH, Left-to-Right Shunt, Einsenmenger Syndrome

Full-Text   Cite this paper   Add to My Lib

Abstract:

Pulmonary arterial hypertension PAH is a progressive disease characterized by an increase in pulmonary arterial pressure and resistance. It often complicates congenital heart disease with a left-to-right shunt. The objective of this study is to evaluate the evolutionary profile of the pulmonary pressures of children with congenital heart disease with left-to-right shunt and to identify the factors favoring an evolution towards PAH. This is a retrospective, descriptive and analytical study over a period of four years and six months (from January 1, 2016 to June 30, 2020) at the Center National d’Enfant Albert Royer in Dakar on a series of 87 cases. The hospital frequency was 3.98 per thousand, and the incidence of PAH was 9.44%. The sex ratio of 0.74. The average age was 44.76 months. The average time between the onset of symptoms and the diagnosis of heart disease is 78.81 days. Dyspnea was found in 70.11% of cases, the burst of pulmonary B2 was found in 55%. Global heart failure was noted in 39.08% of cases. Cardiomegaly was found in 89.66% and pulmonary hypervascularization was found in 57.72% of cases. CIV was present in 54.02% of cases, followed by PCA in 21.14% and CAVc in 18.39% of cases. furosemide was used in 97.70% of cases and Captopril in 74.71% of cases. Sildenafil was used in 10.34% of patients, and 12.64% of patients benefited from surgical management. Eisenmenger syndrome was found in 12.64% of patients. PAH in these heart diseases is a formidable and frequent complication, due to an increase in precapillary flow. The major improvement in mortality and morbidity is early surgical management, in the first months of life, to prevent pulmonary vascular disease.

References

[1]  Jaïs, X., Savale, L., Sitbon, O., Montani, D., Parent, F. and Humbert, M. (2011) Current Treatments for PAH. Réalités Cardiologiques, Notebook 1, 273.
[2]  Oishi, P., Datar, S.A. and Fineman, J.R. (2011) Advances in the Management of Pediatric Pulmonary Hypertension. Respiratory Care, 56, 1314-1339.
https://doi.org/10.4187/respcare.01297
[3]  Blaysat, G. (2010) Pulmonary Arterial Hypertension in Children. Archives of Cardiovascular Diseases Supplements, 2, 126-131.
https://doi.org/10.1016/S1878-6480(10)70360-8
[4]  Humbert, M. and Simonneau, G. (2004) Sildenafil for Pulmonary Arterial Hypertension: Still Waiting for Evidence. American Journal of Respiratory and Critical Care Medicine, 169, 6-7.
https://doi.org/10.1164/rccm.2310007
[5]  Diop, O. (2019) Mortality Linked to Infantile Heart Disease at the Alber Royer National Children’s Hospital Center. Ph. D. Thesis, Cheikh Anta Diop University of Dakar, Dakar, No. 122.
[6]  Mulder, B.J.M. (2010) Changing Demographics of Pulmonary Arterial Hypertension in Congenital Heart Disease. European Respiratory Review, 19, 308-313.
[7]  Rudolph, A.M., Mayer, F.E., Nadas, A.S., et al. (1958) Patient Ductus Arterosus: A Clinical and Hemodynamic Study of 23 Patients in the First Year of Life. Pediatric, 22, 892-903.
https://doi.org/10.1542/peds.22.5.892
[8]  Ndiaye, M., Diarra, O., Ndieng, P.A., et al. (2006) Congenital Heart Disease Operated in Dakar, about 102 Cases. Bibliothequè Centrale de l’université Cheikh Anta DIOP de Dakar, 1, 9-11.
http://196.1.97.20/viewer.php?c=articles&d=cardiopathies%5fcongenitales%5foperees%5fa%5fdakar%5fa%5fpropos%5fde%5f102%5fcas
[9]  Mbaye, A., Bodian, M., Ngaide, A.A., et al. (2017) Congenital Heart Disease in Adolescents and Adults: Management in a General Cardiology Department in Senegal. Annals of Cardiology and Angiology, 66, 217-222.
https://doi.org/10.1016/j.ancard.2017.02.003
[10]  Weitzenblum, E., Canuet, M and Chaouat, A. (2013) PAH of Chronic Respiratory Diseases. EMC Cardiology, 8, 11-037-A-10.
[11]  Suzuki, K., Yamaki, S., Mimori, S., et al. (2000) Pulmonary Vascular Disease in Down’s Syndrome with Complete Atrioventricular Septal Defect. American Journal of Cardiology, 86, 434-437.
https://doi.org/10.1016/S0002-9149(00)00960-7
[12]  Van de Bruaene, A., Delcroix, M., Pasquet, A., et al. (2009) The Belgian Eisenmenger Syndrome Registry: Implications for Treatment Strategies? Acta Cardiologica, 64, 447-453.
https://doi.org/10.2143/AC.64.4.2041608
[13]  Diop, A.K. (2007) Congenital Heart Disease in Dakar: About 72 Cases Collected in the Pediatric Department of the Main Hospital in Dakar. Ph. D. Thesis, Cheikh Anta Diop University, Dakar.
[14]  Bonnet, D., Lévy, M. and Bajolle, F. (2012) Review of Treatments for Pulmonary Arterial Hypertension in Children.
https://www.srlf.org/wp-content/uploads/2015/11/20130116_18-ESRP-D_Bonnet-TraitementsHypertenionArterielle.pdf
[15]  Diop, I.B., Ba, S.A., Sarr, M., et al. (1995) Congenital Heart Disease: Anatomoclinical, Prognostic and Therapeutic Aspects, about 103 Cases Observed at the Cardiology Clinic of the University Hospital of Dakar. Dakar Medical, 40, 181-186.
https://pubmed.ncbi.nlm.nih.gov/9827079/
[16]  Vongpatanasin, W., Brickner, M.E., Hillis, L.D., et al. (1998) The Eisenmenger Syndrome in Adults. Annals of Internal Medicine, 128, 745-755.
https://doi.org/10.7326/0003-4819-128-9-199805010-00008

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133